Can a new biologic calm severe eczema?

NCT ID NCT07762833

Not yet recruiting Disease control Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This clinical trial is testing whether the drug nemolizumab can help treat moderate-to-severe atopic dermatitis (a common type of eczema) in Chinese patients aged 12 and older. Participants will receive either nemolizumab or a placebo (a look-alike with no active drug) every four weeks, and researchers will track improvements in skin symptoms like redness, thickness, and itching. The study aims to see if nemolizumab is more effective than placebo and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nemolizumab
What this could lead to: If successful, nemolizumab could offer a new treatment option for people with moderate-to-severe atopic dermatitis, potentially reducing itch and skin inflammation.
What could go wrong: This is a Phase 3 trial, but it is a bridging study in a specific population (Chinese subjects), so results may not generalize. As with any biologic, there are risks of side effects, and the drug may not prove more effective than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.